Table IV.
Studies investigating the association of ischemic or bleeding events and clopidogrel response with use of VerifyNow assay
| Study author/acronym | Method:agonist | N | Population | Follow-up | Outcome | OR/HR | Cut-off value | Prevalence of HPR/LPR (%) | AUC | PPV (%) | NPV (%) | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | |||||||||||||
| Price et al. [134] | VerifyNow | 380 | PCI | 6 months | MACE | 6.50 | 235 PRU | 32 | 0.71 | 99 | 78 | 68 | |
| Campo et al. [120] | VerifyNow | 300 | PCI | 1 year | MACE | 1.02 | 239 PRU | 13 | 0.87 | 43 | 98 | 81 | 92 |
| Park et al. [198] | VerifyNow | 2849 | PCI+DES | 2.2 years | MACE | NS | 235 PRU | 58 | |||||
| Marcucci et al. [135] | VerifyNow | 683 | ACS+PCI | 1 year | MACE | 2.52 | 240 PRU | 32 | 0.66 | 12 | 96 | 61 | 70 |
| POPULAR [59] | VerifyNow | 1055 | Elective PCI | 1 year | MACE | 2.53 | 236 PRU | 38 | 0.62 | 13 | 94 | 60 | 63 |
| POPULAR [188] | VerifyNow | 422 | Elective PCI | 1 year | MACE | 2.5 | 236 PRU | 25 | |||||
| Cuisset et al. [199] | VerifyNow | 120 | Elective PCI | In hospital | Periprocedural MI | 4.60 | < 15% inhibition | 25 | |||||
| ARMYDA PRO [200] | VerifyNow | 160 | PCI | 1 month | MACE | 6.10 | 240 PRU | 25 | 0.56 | 81 | 53 | ||
| TRILOGY ACS Platelet Function Substudy [201] | VerifyNow | 2564 | ACS treated conservatively | 30 months | MACE | NS | 208 and 230 PRU | Clopidogrel: 45–55% Prasugrel: 10–15% | 0.54 (for 178 PRU) | 47 | 59 | ||
| Bleeding | |||||||||||||
| Campo et al. [120] | VerifyNow | 300 | PCI | 1 year | TIMI major bleeding | 0.94 | 85 PRU | 25 | 0.84 | 21 | 98 | 81 | 80 |
AUC – area under the curve (of the receiver operating curve – c-index), PPV – positive predictive value, NPV – negative predictive value, HPR – high platelet reactivity (prevalence is given for studies investigating thrombotic events), LPR – low platelet reactivity (prevalence is given for studies investigating bleeding events), PCI – percutaneous coronary intervention, ACS – acute coronary syndrome, MACE – major adverse cardiac events, MI – myocardial infarction, ST – stent thrombosis, DES – drug eluting stent, TIMI – thrombolysis in myocardial infraction, NS – not significant.